Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.73
-1.01 (-14.99%)
At close: Feb 20, 2026, 4:00 PM EST
5.79
+0.06 (1.03%)
After-hours: Feb 20, 2026, 7:59 PM EST
Ardelyx Revenue
In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth. Ardelyx had revenue of $125.22M in the quarter ending December 31, 2025, with 7.82% growth.
Revenue (ttm)
$407.32M
Revenue Growth
+22.09%
P/S Ratio
3.45
Revenue / Employee
$1,031,190
Employees
395
Market Cap
1.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immatics | 99.45M |
| Intellia Therapeutics | 57.53M |
| uniQure | 15.75M |
| Zenas BioPharma | 15.00M |
| Capricor Therapeutics | 11.13M |
| AtaiBeckley | 3.02M |
ARDX News
- 15 hours ago - Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability - Seeking Alpha
- 19 hours ago - Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops - Benzinga
- 23 hours ago - Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 - GlobeNewsWire
- 17 days ago - Ardelyx Receives New Patent for Tenapanor - GlobeNewsWire
- 23 days ago - First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA - GlobeNewsWire
- 4 weeks ago - Ardelyx: Assessment Of Acquisition Rumors - Seeking Alpha